Review
Published on 30 Sep 2025
Strategies for the drug development of cancer therapeutics
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1656012
- 381 views
Type at least 3 characters
3,002 articles
Original Research
Published on 30 Sep 2025
Cost-effectiveness analysis of first-line treatments for recurrent or metastatic head and neck cancer in China: an economic evaluation based on network meta-analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1644426
- 362 views
Case Report
Published on 30 Sep 2025
Case Report: Life-threatening cisplatin-induced myelosuppression in pediatric osteosarcoma: molecular mechanisms, pharmacogenomic profiling, and targeted clinical management
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1668180
- 198 views
Correction
Accepted on 29 Sep 2025
Correlation Analysis Between Plasma Concentration of Nilotinib and Clinical Efficacy and Safety in Patients with Chronic Myeloid Leukemia : a single–center retrospective cohort study
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1699696
Original Research
Accepted on 29 Sep 2025
Targeted Degradation of EGFR 19Del by Protac Suppresses Tumor Growth in Non-Small Cell Lung Cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1604661
- 506 views
Original Research
Accepted on 29 Sep 2025
Alkaloid-driven multi-target synergy of Tripterygium wilfordii polyglycosides overcomes cisplatin resistance in ovarian cancer by coordinated inhibition of PTPN11/EGFR/JAK signaling
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1686526
Editorial
Accepted on 29 Sep 2025
Editorial: AI Research in Cancer Pharmacology
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1681113
Review
Accepted on 29 Sep 2025
Iron, Copper and Disulfide Dysregulation: Molecular Crossroads of Metabolic Cell Death in Melanoma Progression
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1685331
Clinical Trial
Accepted on 29 Sep 2025
Assessing the efficacy and safety of pentoxifylline in preventing chemotherapy-induced peripheral neuropathy and mucositis in breast cancer patients
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1678161
Original Research
Accepted on 29 Sep 2025
BYS10, a novel selective RET inhibitor, exhibits potent antitumor activity in preclinical models
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1670140
Case Report
Accepted on 29 Sep 2025
Case Report: Fluzoparib Combined Exemestane in gBRCA2-mutated HR+/HER2− Advanced Breast Cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1673418
Systematic Review
Accepted on 29 Sep 2025
Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (OMOC): A Systematic Review and Meta-Analysis of Clinical Outcomes and Toxicity Profiles
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1620922
General Commentary
Accepted on 29 Sep 2025
The Intersection of Metabolism and Drug Resistance: Multi-omics Analysis of the MEF2D-ACSL3 Axis in Suppressing Ferroptosis in Hepatocellular Carcinoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1575998
Original Research
Published on 29 Sep 2025
Efficacy of single low-dose dexamethasone with NEPA for the 168 h prevention of highly or moderately emetogenic chemotherapy
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1622789
- 449 views
Original Research
Published on 29 Sep 2025
Long-term outcomes of platinum-based chemotherapy for T4 stage sinonasal adenoid cystic carcinoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1623242
- 673 views
Review
Published on 29 Sep 2025
An overview of mechanisms, biomarkers, and treatment strategies for acquired anti-EGFR resistance in RAS wild-type colorectal cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1656372
- 161 views